StimuSIL
Wilmington, US · Founded 2021 · Delaware corporation · 1 known investors
Find your way into StimuSIL
223 people in our graph share verified history with the StimuSIL team — schools, employers, funds. One of them is your warm intro.
StimuSIL is a medical device company developing subdermal photobiomodulation technology that uses patented methods to deliver light-based stimulation beneath the skin's melanin layer for dermatology and aesthetics indications. Its lead preclinical candidate targets androgenetic alopecia (hair loss), with a research pipeline covering vitiligo, psoriasis, wrinkles, cellulite, and acne scars.
Founders & leadership
StimuSIL was founded in 2021 by Ana Isabel Villalba Villar and Ana Villalba.


Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$2.3M disclosed across 4 rounds · 2022–2024
▶$600KraisedMar 2025 · 2 investors · BiotechnologyRule 506(b)
- Abidin GulmusDirector
- Ana Villalba VillarExecutive Officer, Director
- Pablo VillalbaExecutive Officer, Director
- Offering amount
- $600K
- Amount sold
- $600K
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.1MraisedMay 2024 · 7 investors · BiotechnologyRule 506(b)
- Firat YerlikayaDirector
- Pablo VillalbaExecutive Officer, Director
- Ana Villalba VillarExecutive Officer, Director
- Offering amount
- $1.1M
- Amount sold
- $1.1M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$48.8KraisedSep 2023 · 1 investors · BiotechnologyRule 506(b)
- Pablo VillalbaExecutive Officer, Director
- Firat YerlikayaDirector
- Ana Villalba VillarExecutive Officer, Director
- Offering amount
- $48.8K
- Amount sold
- $48.8K
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$575KraisedAug 2022 · 12 investors · BiotechnologyRule 506(b)
- Pablo VillalbaExecutive Officer, Director
- Ana Villalba VillarExecutive Officer, Director
- Firat YerlikayaDirector
- Offering amount
- $575K
- Amount sold
- $575K
- First sale
- Jul 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does StimuSIL do?
- StimuSIL is a medical device company developing subdermal photobiomodulation technology that uses patented methods to deliver light-based stimulation beneath the skin's melanin layer for dermatology and aesthetics indications. Its lead preclinical candidate targets androgenetic alopecia (hair loss), with a research pipeline covering vitiligo, psoriasis, wrinkles, cellulite, and acne scars.
- Who founded StimuSIL?
- StimuSIL was founded by Ana Isabel Villalba Villar, Ana Villalba in 2021.
- Who are StimuSIL's investors?
- StimuSIL's investors include Capital Cell.
- How much funding has StimuSIL raised?
- StimuSIL has disclosed $2.3M raised across 4 rounds.
- Where is StimuSIL headquartered?
- StimuSIL is headquartered in Wilmington, US.

